Clinical Trials Browser

Phase 2 × Bortezomib × Dermatologic × Clear all

NCT00182637 2020-08-03

Bortezomib in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma

Phase 2 Completed

5 enrolled 4 charts

DermatologicLymphoid

Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous

NCT00288041 2013-03-05

Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma

Phase 2 Completed

Uveal Melanoma, Melanoma

NCT00024011 2013-01-16

PS-341 in Treating Patients With Metastatic Malignant Melanoma

Phase 2 Completed

Melanoma

NCT00810576 2012-08-07

Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma

Phase 2 Terminated

1 enrolled 3 charts

DermatologicLymphoid

Subcutaneous panniculitis-like T-cell lymphoma, Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, T-Cell, Lymphoma, T-Cell, Peripheral, Lymphoma, Large-Cell, Anaplastic, Enteropathy-Associated T-Cell Lymphoma